Organogenesis (ORGO) Short Interest Ratio & Short Volume → He cracked the code to crypto… (From Weiss Ratings) (Ad) Free ORGO Stock Alerts $2.97 +0.12 (+4.21%) (As of 05/15/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Organogenesis Short Interest DataCurrent Short Volume9,740,000 sharesPrevious Short Volume8,320,000 sharesChange Vs. Previous Month+17.07%Dollar Volume Sold Short$22.89 millionShort Interest Ratio / Days to Cover10.2Last Record DateApril 30, 2024Outstanding Shares132,570,000 sharesFloat Size77,590,000 sharesShort Percent of Float12.55%Today's Trading Volume579,261 sharesAverage Trading Volume944,163 sharesToday's Volume Vs. Average61% Short Selling Organogenesis ? Sign up to receive the latest short interest report for Organogenesis and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatORGO Short Interest Over TimeORGO Days to Cover Over TimeORGO Percentage of Float Shorted Over Time Ad True Market InsidersExposed: 10 CENT Crypto to Explode May 20th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... Today, he is now making the biggest crypto call of his ENTIRE career…Click For My #1 FREE Crypto for 2024 Organogenesis Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/20249,740,000 shares $22.89 million +17.1%12.6%10.2 $2.35 4/15/20248,320,000 shares $22.96 million +15.1%10.8%10.7 $2.76 3/31/20247,230,000 shares $20.53 million -9.7%9.4%9.4 $2.84 3/15/20248,010,000 shares $22.83 million +5.8%10.3%11.5 $2.85 2/29/20247,570,000 shares $27.02 million +1.3%9.8%9.9 $3.57 2/15/20247,470,000 shares $27.49 million +11.3%9.4%10.2 $3.68 Get the Latest News and Ratings for ORGO and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Organogenesis and its competitors with MarketBeat's FREE daily newsletter. 1/31/20246,710,000 shares $22.14 million +4.2%8.5%6.9 $3.30 1/15/20246,440,000 shares $25.24 million +56.7%8.2%6.6 $3.92 12/31/20234,110,000 shares $16.81 million -15.4%5.2%4.3 $4.09 12/15/20234,860,000 shares $18.23 million +4.1%6.2%5 $3.75 11/30/20234,670,000 shares $11.91 million -0.4%6.0%5.1 $2.55 11/15/20234,690,000 shares $11.87 million -1.7%6.0%5.4 $2.53 10/31/20234,770,000 shares $10.68 million +12.8%6.1%5 $2.24 10/15/20234,230,000 shares $9.98 million +8.2%5.4%5.1 $2.36 9/30/20233,910,000 shares $12.43 million +1.6%5.0%4.4 $3.18 9/15/20233,850,000 shares $9.43 million +25.8%4.9%4.5 $2.45 8/31/20233,060,000 shares $8.57 million +8.1%3.9%3.4 $2.80 8/15/20232,830,000 shares $7.58 million -16.5%3.6%2.8 $2.68 7/31/20233,390,000 shares $14.48 million -0.6%4.4%3.1 $4.27 7/15/20233,410,000 shares $13.30 million -7.3%5.1%3.2 $3.90 6/30/20233,680,000 shares $12.22 million -7.5%5.5%3.7 $3.32 6/15/20233,980,000 shares $16.36 million -14.0%5.9%3.8 $4.11 5/31/20234,630,000 shares $16.81 million -10.1%6.9%3.2 $3.63 5/15/20235,150,000 shares $16.38 million +0.8%7.7%3.5 $3.18 4/30/20235,110,000 shares $10.48 million +0.2%7.6%4 $2.05 4/15/20235,100,000 shares $10.56 million -1.5%7.6%4.1 $2.07 3/31/20235,180,000 shares $11.03 million -35.8%7.7%4.1 $2.13 3/15/20238,070,000 shares $17.43 million +1.3%12.1%6.5 $2.16 2/28/20237,970,000 shares $19.53 million +12.4%11.9%10 $2.45 2/15/20237,090,000 shares $20.70 million +12.2%10.2%10.7 $2.92 1/31/20236,320,000 shares $16.18 million +9.9%9.2%9.4 $2.56 1/15/20235,750,000 shares $14.89 million +2.0%8.4%9.2 $2.59 12/30/20225,640,000 shares $15.17 million +14.6%8.2%9.3 $2.69 12/15/20224,920,000 shares $12.50 million +4.9%7.8%8.1 $2.54 11/30/20224,690,000 shares $12.85 million -20.9%7.4%6.4 $2.74 11/15/20225,930,000 shares $17.02 million -0.7%9.3%6.9 $2.87 10/31/20225,970,000 shares $19.58 million +5.1%9.4%6.4 $3.28 10/15/20225,680,000 shares $18.18 million -1.1%9.0%5.7 $3.20 9/30/20225,740,000 shares $18.60 million -17.5%9.0%5.3 $3.24 9/15/20226,960,000 shares $24.78 million +7.4%11.0%5.9 $3.56This is the best new way to score with AI (Ad)If you thought that you missed your chance to score big on AI, I have great news. A rare second profit window is starting to open.Click now for the best way into the newest AI projects ORGO Short Interest - Frequently Asked Questions What is Organogenesis' current short interest? Short interest is the volume of Organogenesis shares that have been sold short but have not yet been closed out or covered. As of April 30th, traders have sold 9,740,000 shares of ORGO short. 12.55% of Organogenesis' shares are currently sold short. Learn More on Organogenesis' current short interest. What is a good short interest ratio for Organogenesis? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ORGO shares currently have a short interest ratio of 10.0. Learn More on Organogenesis's short interest ratio. What is a good short interest percentage for Organogenesis? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 12.55% of Organogenesis' floating shares are currently sold short. Is Organogenesis' short interest increasing or decreasing? Organogenesis saw a increase in short interest in April. As of April 30th, there was short interest totaling 9,740,000 shares, an increase of 17.1% from the previous total of 8,320,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Organogenesis' float size? Organogenesis currently has issued a total of 132,570,000 shares. Some of Organogenesis' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Organogenesis currently has a public float of 77,590,000 shares. How does Organogenesis' short interest compare to its competitors? 12.55% of Organogenesis' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Organogenesis: Amarin Co. plc (3.94%), Terns Pharmaceuticals, Inc. (10.91%), Revance Therapeutics, Inc. (11.77%), AC Immune SA (0.88%), Korro Bio, Inc. (2.68%), Verrica Pharmaceuticals Inc. (14.05%), Shattuck Labs, Inc. (4.29%), Neurogene Inc. (8.85%), Nanobiotix S.A. (0.12%), Esperion Therapeutics, Inc. (11.79%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short Organogenesis stock? Short selling ORGO is an investing strategy that aims to generate trading profit from Organogenesis as its price is falling. ORGO shares are trading up $0.07 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Organogenesis? A short squeeze for Organogenesis occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of ORGO, which in turn drives the price of the stock up even further. How often is Organogenesis' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ORGO, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: AMRN Short Interest Data TERN Short Interest Data RVNC Short Interest Data ACIU Short Interest Data KRRO Short Interest Data VRCA Short Interest Data STTK Short Interest Data NGNE Short Interest Data NBTX Short Interest Data ESPR Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ORGO) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingAmazon's betting big on this unknown AI companyManward PressThis Wall Street stock prediction just went viralChaikin AnalyticsWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks News[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap Sniper